Delivery Order SPE2DB22D3301-SPE2DB25FZ0UB
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 120 ml quantities, valued at $4,567.35. This delivery order represents a firm fixed price, non-set-aside contract utilizing AmerisourceBergen's existing Indefinite Delivery Contract vehicle with DLA Troop Support Medical. The product will be performed at AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania, with...
- The Defense Logistics Agency awarded a delivery order contract to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. This is a firm fixed-price delivery order with a ceiling value of $3,763.02 and an ultimate completion date of July 28, 2025. The contract was competitively awarded without set-aside restrictions and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This...
- The Defense Logistics Agency's Medical Supply Chain awarded a delivery order valued at $5,357.13 to AmerisourceBergen Drug Corp for Quillivant XR oral suspension (150mL, 5mg/mL) on August 11, 2025, with completion scheduled for August 12, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Quillivant XR is a long-acting formulation of methylphenidate used to treat...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension in a 120 ml quantity, valued at $2,363.38. This firm fixed-price delivery order, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical designated SPE2DX. The contract involved no set-aside designation and was...
- The Defense Logistics Agency awarded a delivery order valued at $1,909.60 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (180 ml) on September 10, 2025, with completion scheduled for September 11, 2025. This competitively awarded, firm fixed-price delivery order represents a non-set-aside contract and is being performed at the awardee's corporate headquarters in Conshohocken, Pennsylvania. The contract is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,859.94 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 mL suspension in a 120 mL container. The contract was competitively awarded with no set-aside designation and carries a firm fixed price structure, with an ultimate completion date of July 31, 2025. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania, will perform the work at its corporate office location in the same city. This delivery...
- The Defense Logistics Agency awarded a delivery order valued at $2,477.61 to AmerisourceBergen Drug Corp on August 25, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in a 150 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, indicating competitive award, and is scheduled for completion by August 26, 2025. The product will be delivered to the Conshohocken, Pennsylvania location, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order valued at $2,050.33 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 mL suspension (180 mL) on August 22, 2025, with an ultimate completion date of August 25, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The award represents a child delivery order issued under AmerisourceBergen's larger...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp, the prime contractor on a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 through December 2026, to supply Quillivant XR 25 mg/5 ml suspension in a 150ml quantity. This firm fixed-price delivery order, valued at $1,577.04, was competitively awarded without a set-aside designation and is scheduled for completion by July 31, 2025. The product will be delivered to AmerisourceBergen's facility in...
- SPE2DB22D3301Indefinite Delivery Contract
- SPE2DB22D3301-SPE2DB25FZ0UBDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) with a contract value of $3,967.69. This non-set-aside, firm fixed price delivery order was awarded on September 10, 2025, with an ultimate completion date of September 11, 2025. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. Quillivant XR is a brand-name extended-release amphetamine-based medication used to treat attention-deficit/hyperactivity disorder (ADHD). As a prime vendor under the DLA's pharmaceutical supply program, AmerisourceBergen is a critical distributor of medications and medical supplies supporting military healthcare systems, the Defense Health Agency, and other federal medical procurement needs. The company's federal contract portfolio demonstrates extensive experience delivering a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains to support military personnel, veterans, and other federal healthcare beneficiaries.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.0k | 9/10/25 |